 | Sagar Uday Nigwekar |
Prominent publications by Sagar Uday Nigwekar
BACKGROUND: People with chronic kidney disease (CKD) have higher risks of cardiovascular disease compared to the general population. Specifically, cardiovascular deaths account most deaths in kidney transplant recipients. Statins are a potentially beneficial intervention for kidney transplant patients given their established benefits in patients at risk of cardiovascular disease in the general population. This is an update of a review first published in 2009.
OBJECTIVES: We aimed to ...
| Also Ranks for: Kidney Transplant Recipients | cardiovascular events | coa reductase | placebo treatment | statins mortality |
BACKGROUND: People with advanced kidney disease treated with dialysis experience mortality rates from cardiovascular disease that are substantially higher than for the general population. Studies that have assessed the benefits of statins (HMG CoA reductase inhibitors) report conflicting conclusions for people on dialysis and existing meta-analyses have not had sufficient power to determine whether the effects of statins vary with severity of kidney disease. Recently, additional data for ...
| Also Ranks for: Dialysis Patients | 95 statins | reductase inhibitors | cardiovascular events | treatment effects |
BACKGROUND: Treatment with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is increasingly used to reduce proteinuria and retard the progression of chronic kidney disease (CKD). But some patients do not attain complete resolution of proteinuria and might have higher aldosterone levels within few months of treatment. The addition of aldosterone antagonists may be beneficial to these patients for reduction of progression of renal damage.
OBJECTIVES: ...
| Also Ranks for: Aldosterone Antagonists | acei arb | chronic kidney | patients ckd | and or |
BACKGROUND: Cardiovascular disease accounts for more than half the number of deaths among dialysis patients. The role of HMG CoA reductase inhibitors (statins) in the treatment of dyslipidaemia in dialysis patients is unclear and their safety has not been established.
OBJECTIVES: To assess the benefits and harms of statins in peritoneal dialysis (PD) and haemodialysis patients (HD).
SEARCH STRATEGY: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled trials (CENTRAL, ...
| Also Ranks for: Dialysis Patients | reductase inhibitors | 95 cardiovascular mortality | placebo treatment | hmg coa |
BACKGROUND: Cardiovascular deaths account for the majority of deaths in kidney transplant recipients and dyslipidaemia contributes significantly to their cardiovascular disease. Statins are widely used in kidney transplant patients given their established benefits in the general population, however evidence favouring their use is lacking.
OBJECTIVES: To assess the benefits and harms of statin therapy on mortality and renal outcomes in kidney transplant recipients.
SEARCH STRATEGY: We ...
| Also Ranks for: Kidney Transplant Recipients | reductase inhibitors | statins placebo | cardiovascular mortality | statin therapy |
OBJECTIVE: To systematically review the effect of folic acid based homocysteine lowering on cardiovascular outcomes in people with kidney disease.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, the Cochrane Library, and ClinicalTrials.gov to June 2011.
STUDY SELECTION: Randomised trials in people with non-dialysis dependent chronic kidney disease or end stage kidney disease or with a functioning kidney transplant reporting at least 100 patient years of ...
| Also Ranks for: Cardiovascular Events | kidney disease | folic acid | homocysteine lowering | myocardial infarction |
Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis
[ PUBLICATION ]
BACKGROUND AND OBJECTIVES: Addition of aldosterone antagonists (AA) might provide renal benefits to proteinuric chronic kidney disease (CKD) patients over and above the inhibition of renin-angiotensin system blockers (RAS). We evaluated the benefits and harms of adding selective and nonselective AA in CKD patients already on RAS.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: MEDLINE, EMBASE, and Renal Health Library were searched for relevant randomized clinical trials in adult CKD ...
| Also Ranks for: Aldosterone Antagonists | chronic kidney | ckd patients | risk hyperkalemia | acei arb |
Chronic kidney disease-mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was ...
| Also Ranks for: Chronic Kidney | bone disorder | clinical practice guideline | treatment ckdmbd | disease ckd |
HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype
[ PUBLICATION ]
Aortic calcification is an important independent predictor of future cardiovascular events. We performed a genome-wide association meta-analysis to determine SNPs associated with the extent of abdominal aortic calcification (n = 9,417) or descending thoracic aortic calcification (n = 8,422). Two genetic loci, HDAC9 and RAP1GAP, were associated with abdominal aortic calcification at a genome-wide level (P < 5.0 × 10−8). No SNPs were associated with thoracic aortic calcification at the ...
| Also Ranks for: Aortic Calcification | smooth muscle | abdominal aorta | genome wide | genetic loci |
Kidney Function Decline among Black Patients with Sickle Cell Trait and Sickle Cell Disease: An Observational Cohort Study.
[ PUBLICATION ]
BACKGROUND: Sickle cell trait and sickle cell disease are thought to be independent risk factors for CKD, but the trajectory and predictors of kidney function decline in patients with these phenotypes are not well understood.
METHODS: Our multicenter, observational study used registry data (collected January 2005 through June 2018) and included adult black patients with sickle cell trait or disease (exposures) or normal hemoglobin phenotype (reference) status (ascertained by ...
| Also Ranks for: Sickle Cell Trait | cell disease | black patients | kidney function | registry data |
Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
[ PUBLICATION ]
CONTEXT: It is uncertain which osteoporosis therapy is more effective: bisphosphonates or denosumab.
OBJECTIVE: To determine whether denosumab therapy increases bone mineral density (BMD) and reduces fracture risk more so than bisphosphonates in patients with low BMD or osteoporosis.
METHODS: The PubMed, Embase, and the Cochrane Library databases were searched through November 2018 for head-to-head, randomized, controlled trials comparing denosumab and bisphosphonates among adult ...
| Also Ranks for: Randomized Controlled | denosumab bmd | patients osteoporosis | 12 months | lumbar spine |
BACKGROUND AND OBJECTIVES: Severe hyponatremia (<120 mEq/L) in hospitalized patients has a high mortality rate. We hypothesized that underlying diseases causing hyponatremia attribute to mortality rather than hyponatremia itself.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The relationship between mortality and serum sodium (sNa) was examined in 45,693 patients admitted to a single community teaching hospital between January 1996 and December 2007. We conducted a comprehensive ...
| Also Ranks for: Patients Hyponatremia | serum sodium | 120 meq | mortality rate | underlying diseases |
BACKGROUND: Cardiovascular disease accounts for more than half the number of deaths among dialysis patients. The role of HMG CoA reductase inhibitors (statins) in the treatment of dyslipidaemia in dialysis patients is unclear and their safety has not been established.
OBJECTIVES: To assess the benefits and harms of statins in peritoneal dialysis (PD) and haemodialysis patients (HD).
SEARCH STRATEGY: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled trials (CENTRAL, ...
| Also Ranks for: Dialysis Patients | statins placebo | reductase inhibitors | cardiovascular disease | humans hydroxymethylglutaryl |
Referral to Nephrologists for Chronic Kidney Disease Care: Is Non-Diabetic Kidney Disease Ignored?
[ PUBLICATION ]
BACKGROUND: Late referral to nephrologists is common and associated with increased morbidity and mortality. We aimed to analyze the prevalence rates, predictors and consequences of late referral to nephrologists by primary care physicians for chronic kidney disease (CKD) care.
METHODS: A retrospective analysis of 204 patients started on dialysis for CKD in two community hospitals between March 2003 and March 2005 was conducted. Relevant clinical and laboratory data were obtained from the ...
| Also Ranks for: Late Referral | kidney disease | retrospective analysis | primary physicians | patients ckd |
Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease
[ PUBLICATION ]
BACKGROUND: Insulin resistance is associated with increased sympathetic and reduced parasympathetic activity. Resting heart rate reflects autonomic activity. Therefore, we examined the associations of resting heart rate with insulin resistance, cardiovascular events and mortality in the moderate chronic kidney disease (CKD) population.
METHODS: Four hundred and sixty participants with MDRD GFR <60 ml/min/1.73 m(2) in the limited access Atherosclerosis Risk in Communities (ARIC) study ...
| Also Ranks for: Heart Rate | insulin resistance | chronic kidney | metabolic syndrome | cardiovascular events |
Sagar Uday Nigwekar: Influence Statistics
| Concept | World rank |
|---|---|
| micronutrient iron deficiencies | #1 |
| efficacy calcification scores | #1 |
| penile calciphylaxis mortality | #1 |
| calciphylaxis remains | #1 |
| sts adverse events | #1 |
| trait sickle | #1 |
| thiosulfates uremia | #1 |
| olfactory dysfunction ckd | #1 |
| adequate specimens calciphylaxis | #1 |
| painful retiform | #1 |
| nonpenile calciphylaxis | #1 |
| noncalciphylaxis patients calciphylaxis | #1 |
| patients calciphylaxis | #1 |
| bmd sts | #1 |
| calciphylaxis risk factors | #1 |
| calciphylaxis correlation | #1 |
| sts bmd | #1 |
| intravenous sodium thiosulphate | #1 |
| developed calciphylaxis | #1 |
| histologic findings calciphylaxis | #1 |
| summary multidisciplinary approach | #1 |
| calciphylaxis chelating | #1 |
| 95 rrt | #1 |
| sna 120 meq | #1 |
| ckd vulnerable population | #1 |
| association olfactory | #1 |
| rare thrombotic vasculopathy | #1 |
| calciphylaxis risk | #1 |
| calciphylaxis fatal | #1 |
| chapter evidencebased summary | #1 |
| clinical investigational studies | #1 |
| causal pathways development | #1 |
| specimen biorepositories | #1 |
| capillaries medium | #1 |
| secondary hyperparathyroidism micronutrient | #1 |
| nonuremic | #1 |
| conditions calciphylaxis | #1 |
| prevalence gustatory dysfunction | #1 |
| ckd intravascular thrombosis | #1 |
| cua management | #1 |
| administration cua | #1 |
| calciphylaxis chronic | #1 |
| investigational studies patients | #1 |
Key People For Dialysis Patients
Sagar Uday Nigwekar:Expert Impact
Concepts for whichSagar Uday Nigwekarhas direct influence:Dialysis patients, Sickle cell trait, Patients calciphylaxis, Chronic kidney disease, Kidney disease, Hip fracture, Kidney transplant recipients, Aldosterone antagonists.
Sagar Uday Nigwekar:KOL impact
Concepts related to the work of other authors for whichfor which Sagar Uday Nigwekar has influence:Chronic kidney disease, Acute kidney injury, Vascular calcification, Cardiac surgery, Dialysis patients, Sodium thiosulfate, Renal function.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |